Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Deutsche Bank downgrades Oxford BioMedica to 'hold' over slower revenue realization

Deutsche Bank has downgraded Oxford BioMedica from "buy" to "hold" and cut its scenario-based price target from 800 pence to 595 pence. The reasons are a slower conversion of demand into reported revenues, delays in programs and operational issues at the Durham site. The bank reduced its revenue estimates for 2026 and 2027 by about 20%, which weighs more heavily on profit and EBITDA. Deutsche Bank now places the onus of proof on execution and views the capital markets day as an important test for management. » More on de.investing.com
Oxford BioMedica cuts full-year revenue forecast sharply, shares plunge

Oxford BioMedica has reduced its 2026 revenue forecast to £180–200 million from £220–240 million previously. The stock fell about 18% to an intraday low and is trading near its 52-week low after management cited short-term changes in customer ordering behavior as the reason. The forecast revision deals a heavy blow to the recently confirmed targets and has led to a marked loss of investor confidence. » More on de.investing.com
Oxford Biomedica: executives exercise options and sell shares

Two executives of Oxford Biomedica, Natalie Walter and Lisa Doman, exercised stock options and subsequently sold shares on the London Stock Exchange. Walter exercised 3,057 options under the Save As You Earn scheme at £2.944 and disposed of the shares at an average of £6.3939 (proceeds approx. £19,546). Doman exercised 10,591 options from the Deferred Bonus Plan free of charge and 2,709 options from the Executive Share Option Scheme at £4.966, and sold a total of 13,300 shares at an average of £6.35 (volume approx. £84,455). The transactions were disclosed in accordance with the EU Market Abuse Regulation. » More on de.investing.com

Financials

In the last quarter, Oxford BioMedica had revenue of €92.68m and net profit of -€42.9m

(EUR)	June 2026	YoY
Revenue	92.68m	-
Gross profit	33.49m	-
Net profit	-42.9m	-
EBITDA	-12.28m	-

Fundamentals

Metric	Value
Market capitalization	€781.24m
Number of shares	121.05m
52-week high/low	€11.52 - €5.03
Dividends	No
Beta	1.11
P/E ratio	-15.60
PEG ratio	2.20
P/B ratio	11.23
P/S ratio	3.72

Company profile

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Name	Oxford BioMedica
CEO	Frank Mathias
Headquarters	Oxford, oxf United Kingdom
Website	oxfordbiomedica.co.uk
Sector	Health Care
Industry	Pharmaceuticals
IPO	13/12/1996
Employees	1,017